Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo to Present Qwo\u2122 (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Isofol Medical","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$103.0 million","newsHeadline":"Isofol Announces Licensing Agreement for Paladin Labs Inc. To Commercialize Arfolitixorin in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$540.0 million","newsHeadline":"Endo Completes Acquisition of BioSpecifics","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Petros Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Authorized Generic Version of Noxafil\u00ae (posaconazole) Oral Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Endo Pharm

    Menu

    Endo Pharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Endo Pharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

              Details:

              Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane.

              Lead Product(s): Posaconazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Noxafil-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo Pharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)

              Details:

              STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.

              Lead Product(s): Avanafil

              Therapeutic Area: Psychiatry/Psychology Product Name: Stendra

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Petros Pharmaceuticals

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PALADIN LABS

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

              Details:

              Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.

              Lead Product(s): Abaloparatide Acetate

              Therapeutic Area: Musculoskeletal Product Name: BA058

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Endo International

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo Pharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Completes Acquisition of BioSpecifics

              Details:

              BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Urology Product Name: Xiaflex

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: BioSpecifics

              Deal Size: $540.0 million Upfront Cash: $540.0 million

              Deal Type: Acquisition December 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PALADIN LABS

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Isofol Announces Licensing Agreement for Paladin Labs Inc. To Commercialize Arfolitixorin in Canada

              Details:

              The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market for arfolitixorin.

              Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Isofol Medical

              Deal Size: $100.0 million Upfront Cash: $103.0 million

              Deal Type: Licensing Agreement November 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo Pharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo to Present Qwo™ (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)

              Details:

              Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.

              Lead Product(s): Collagenase Clostridium Histolyticum

              Therapeutic Area: Dermatology Product Name: Qwo

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY